This indicates that the combination of anti-PD-1/PD-L1 and anti-CD73 mAbs or A2aR antagonist can be more effective in exerting the synergistic effect of anti-tumor T cell-mediated immunotherapy. This evidence concerns the gene ADORA2A and neoplasm.